Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 551

1.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Review.

PMID:
18754026
3.

Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Kawamata N, Ogawa S, Yamamoto G, Lehmann S, Levine RL, Pikman Y, Nannya Y, Sanada M, Miller CW, Gilliland DG, Koeffler HP.

Exp Hematol. 2008 Nov;36(11):1471-9. doi: 10.1016/j.exphem.2008.06.006.

PMID:
18723266
4.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005.

PMID:
19616600
5.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113.

6.
7.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Review.

PMID:
18566540
8.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Review.

PMID:
18496562
9.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
10.

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.

Tefferi A.

Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221. Review.

11.
12.

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.

Asian Pac J Cancer Prev. 2016;17(3):923-6. Review.

13.

Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Lieu CH, Shen YJ, Lai WC, Tsai WH, Hsu HC.

J Chin Med Assoc. 2010 Oct;73(10):530-2. doi: 10.1016/S1726-4901(10)70115-5.

14.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
15.

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.

Asian Pac J Cancer Prev. 2015;16(12):5013-8.

16.

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].

Liu L, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):239-43. Review. Chinese.

PMID:
21362261
17.

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.

Plo I, Vainchenker W.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S329-39. doi: 10.3816/CLM.2009.s.032. Review.

PMID:
19778861
18.

Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.

Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M.

Leukemia. 2009 Sep;23(9):1577-86. doi: 10.1038/leu.2009.85.

PMID:
19387466
19.
20.

Molecular genetic evaluation of myeloproliferative neoplasms.

Azzato EM, Bagg A.

Int J Lab Hematol. 2015 May;37 Suppl 1:61-71. doi: 10.1111/ijlh.12353. Review.

PMID:
25976962
Items per page

Supplemental Content

Support Center